1
|
Kim HI, Han Y, Kim MH, Boo M, Cho KJ, Kim HL, Lee IS, Jung JH, Kim W, Um JY, Park J, Ko SG. The multi-herbal decoction SH003 alleviates LPS-induced acute lung injury by targeting inflammasome and extracellular traps in neutrophils. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2024; 133:155926. [PMID: 39128302 DOI: 10.1016/j.phymed.2024.155926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 07/07/2024] [Accepted: 07/28/2024] [Indexed: 08/13/2024]
Abstract
BACKGROUND Acute lung injury (ALI) is a devastating condition caused by sepsis, pneumonia, trauma, and more recently, COVID-19. SH003, an herbal formula consisted of Astragalus membranaceus, Angelica gigas and Trichosanthes kirilowii, is known for its effects on cancer and immunoregulation. HYPOTHESIS/PURPOSE Previous studies show SH003 exerts a promising anti-inflammatory effect. This study investigates the effect of modified SH003 on ALI using in silico, in vivo, and in vitro models. STUDY DESIGN AND METHODS We performed in silico-based analysis of SH003 on ALI-related pathways. C57BL/6 mice were intraperitoneally subjected to lipopolysaccharide (LPS) to induce septic ALI, followed by oral administration of SH003 for 2 weeks. Dexamethasone was used as the positive control. Human peripheral blood-derived polymorphonuclear neutrophils (PMN) were used to investigate the effect and mechanisms of SH003 on neutrophil extracellular trap (NET) formation. RESULTS Network pharmacology analysis suggested SH003 regulates lung inflammation by modulating NET formation. SH003 significantly reduced mortality in sepsis in vivo by inhibiting local and systemic inflammation, likely via nuclear factor kappa B and mitogen-activated protein kinase pathways-mediated inflammasome suppression. SH003 also decreased NET-related markers in lung tissues and inhibited LPS- and phorbol myristate acetate-induced NET formation in PMN. Cytometry time-of-flight analysis confirmed regulation of NETosis-related pathways by SH003. CONCLUSION SH003 effectively inhibits excessive immune responses in the lung by suppressing inflammasome activation and NET formation. These findings suggest SH003 as a potential therapeutic agent for septic ALI.
Collapse
Affiliation(s)
- Hyo In Kim
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
| | - Yohan Han
- Department of Microbiology and Sarcopenia Total Solution Center, Wonkwang University School of Medicine, Iksan, Republic of Korea
| | - Mi-Hye Kim
- College of Korean Medicine, Woosuk University, Jeonju, Republic of Korea
| | - Mina Boo
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea
| | - Kwang-Jin Cho
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea
| | - Hye-Lin Kim
- College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
| | - In-Seon Lee
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
| | - Ji Hoon Jung
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
| | - Woojin Kim
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea; Korean Medicine-Based Drug Repositioning Cancer Research Center, Kyung Hee University, Seoul, Republic of Korea
| | - Jae-Young Um
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
| | - Jinbong Park
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea; Korean Medicine-Based Drug Repositioning Cancer Research Center, Kyung Hee University, Seoul, Republic of Korea.
| | - Seong-Gyu Ko
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea; Korean Medicine-Based Drug Repositioning Cancer Research Center, Kyung Hee University, Seoul, Republic of Korea.
| |
Collapse
|
2
|
Choi YJ, Lee K, Lee SY, Kwon Y, Woo J, Jeon CY, Ko SG. p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis. Cancer Cell Int 2024; 24:156. [PMID: 38704578 PMCID: PMC11069295 DOI: 10.1186/s12935-024-03337-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 04/18/2024] [Indexed: 05/06/2024] Open
Abstract
BACKGROUND Identifying molecular biomarkers for predicting responses to anti-cancer drugs can enhance treatment precision and minimize side effects. This study investigated the novel cancer-targeting mechanism of combining SH003, an herbal medicine, with docetaxel in non-small cell lung cancer (NSCLC) cells. Also, the present study aimed to identify the genetic characteristics of cancer cells susceptible to this combination. METHODS Cell viability was analyzed by WST-8 assay. Apoptosis induction, BrdU incorporation, and cell cycle analysis were performed using flow cytometry. Metabolites were measured by LC-MS/MS analysis. Real-time PCR and western blotting evaluated RNA and protein expression. DNA damage was quantified through immunofluorescence. cBioPortal and GEPIA data were utilized to explore the mutual co-occurrence of TP53 and UMPS and UMPS gene expression in NSCLC. RESULTS The combination treatment suppressed de novo pyrimidine nucleotide biosynthesis by reducing the expression of related enzymes. This blockade of pyrimidine metabolism led to DNA damage and subsequent apoptosis, revealing a novel mechanism for inducing lung cancer cell death with this combination. However, some lung cancer cells exhibited distinct responses to the combination treatment that inhibited pyrimidine metabolism. The differences in sensitivity in lung cancer cells were determined by the TP53 gene status. TP53 wild-type lung cancer cells were effectively inhibited by the combination treatment through p53 activation, while TP53 mutant- or null-type cells exhibited lower sensitivity. CONCLUSIONS This study, for the first time, established a link between cancer cell genetic features and treatment response to simultaneous SH003 and docetaxel treatment. It highlights the significance of p53 as a predictive factor for susceptibility to this combination treatment. These findings also suggest that p53 status could serve as a crucial criterion in selecting appropriate therapeutic strategies for targeting pyrimidine metabolism in lung cancer.
Collapse
Affiliation(s)
- Yu-Jeong Choi
- Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Korea
| | - Kangwook Lee
- Department of Food and Biotechnology, Korea University, Sejong, Korea
| | - Seo Yeon Lee
- Department of Internal Medicine, Yale University, New Haven, CT, USA
| | - Youngbin Kwon
- Department of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Korea
| | - Jaehyuk Woo
- Department of Korean Medicine, Graduate School, Kyung Hee University, Seoul, Korea
| | - Chan-Yong Jeon
- Department of Internal Medicine, College of Korean Medicine, Gachon University, Gyeonggi-Do, Korea
| | - Seong-Gyu Ko
- Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Korea.
| |
Collapse
|
3
|
Zhou BH, Ding HY, Yang JY, Chai J, Guo HW, Tian EJ. Diclazuril-induced expression of CDK-related kinase 2 in the second-generation merozoites of Eimeria tenella. Mol Biochem Parasitol 2023; 255:111575. [PMID: 37302489 DOI: 10.1016/j.molbiopara.2023.111575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/23/2023] [Accepted: 06/06/2023] [Indexed: 06/13/2023]
Abstract
Diclazuril is a classic anticoccidial drug. The key molecules of diclazuril in anticoccidial action allows target screening for the development of anticoccidial drugs. Cyclin-dependent kinases (CDK) are prominent target proteins in apicomplexan parasites. In this study, a diclazuril anticoccidiosis animal model was established, and the transcription and translation levels of the CDK-related kinase 2 of Eimeria tenella (EtCRK2) were detected. mRNA and protein expression levels of EtCRK2 decreased in the infected/diclazuril group compared with those in the infected/control group. In addition, immunofluorescence analysis showed that EtCRK2 was localised in the cytoplasm of the merozoites. The fluorescence intensity of EtCRK2 in the infected/diclazuril group was significantly weaker than that in the infected/control group. The anticoccidial drug diclazuril against E.tenella affects the expression pattern of EtCRK2 molecule, and EtCRK2 is a potential target for new drug development.
Collapse
Affiliation(s)
- Bian-Hua Zhou
- College of Animal Science and Technology, Henan University of Science and Technology, Kaiyuan Avenue 263, Luolong District, Luoyang 471023, Henan, People's Republic of China.
| | - Hai-Yan Ding
- College of Animal Science and Technology, Henan University of Science and Technology, Kaiyuan Avenue 263, Luolong District, Luoyang 471023, Henan, People's Republic of China
| | - Jing-Yun Yang
- College of Animal Science and Technology, Henan University of Science and Technology, Kaiyuan Avenue 263, Luolong District, Luoyang 471023, Henan, People's Republic of China
| | - Jun Chai
- School of information technology and urban construction, Luoyang Vocational and Technical College, Keji Avenue 6, Yibin District, Luoyang 471934, Henan, People's Republic of China
| | - Hong-Wei Guo
- College of Animal Science & Technology, Henan University of Animal Husbandry and Economy, Longzi Hubei Road 6, Zhengzhou 450046, Henan, People's Republic of China
| | - Er-Jie Tian
- College of Animal Science and Technology, Henan University of Science and Technology, Kaiyuan Avenue 263, Luolong District, Luoyang 471023, Henan, People's Republic of China
| |
Collapse
|
4
|
Han NR, Park HJ, Ko SG, Moon PD. The Mixture of Natural Products SH003 Exerts Anti-Melanoma Effects through the Modulation of PD-L1 in B16F10 Cells. Nutrients 2023; 15:2790. [PMID: 37375695 DOI: 10.3390/nu15122790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Revised: 06/16/2023] [Accepted: 06/17/2023] [Indexed: 06/29/2023] Open
Abstract
Melanoma is the most invasive and lethal skin cancer. Recently, PD-1/PD-L1 pathway modulation has been applied to cancer therapy due to its remarkable clinical efficacy. SH003, a mixture of natural products derived from Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, and formononetin (FMN), an active constituent of SH003, exhibit anti-cancer and anti-oxidant properties. However, few studies have reported on the anti-melanoma activities of SH003 and FMN. This work aimed to elucidate the anti-melanoma effects of SH003 and FMN through the PD-1/PD-L1 pathway, using B16F10 cells and CTLL-2 cells. Results showed that SH003 and FMN reduced melanin content and tyrosinase activity induced by α-MSH. Moreover, SH003 and FMN suppressed B16F10 growth and arrested cells at the G2/M phase. SH003 and FMN also led to cell apoptosis with increases in PARP and caspase-3 activation. The pro-apoptotic effects were further enhanced when combined with cisplatin. In addition, SH003 and FMN reversed the increased PD-L1 and STAT1 phosphorylation levels induced by cisplatin in the presence of IFN-γ. SH003 and FMN also enhanced the cytotoxicity of CTLL-2 cells against B16F10 cells. Therefore, the mixture of natural products SH003 demonstrates therapeutic potential in cancer treatment by exerting anti-melanoma effects through the PD-1/PD-L1 pathway.
Collapse
Affiliation(s)
- Na-Ra Han
- College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Hi-Joon Park
- Department of Anatomy & Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Seong-Gyu Ko
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
- Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Phil-Dong Moon
- Center for Converging Humanities, Kyung Hee University, Seoul 02447, Republic of Korea
| |
Collapse
|
5
|
Han NR, Park HJ, Ko SG, Moon PD. The Protective Effect of a Functional Food Consisting of Astragalus membranaceus, Trichosanthes kirilowii, and Angelica gigas or Its Active Component Formononetin against Inflammatory Skin Disorders through Suppression of TSLP via MDM2/HIF1α Signaling Pathways. Foods 2023; 12:foods12020276. [PMID: 36673369 PMCID: PMC9858287 DOI: 10.3390/foods12020276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 12/22/2022] [Accepted: 01/04/2023] [Indexed: 01/11/2023] Open
Abstract
An herbal mixture (SH003) of Astragalus membranaceus, Trichosanthes kirilowii, and Angelica gigas exhibits therapeutic effects on carcinomas and immunosuppression. However, the role of JRP-SNF102, which is an advanced mixture of SH003, in regulating inflammatory responses is unexplored. We aim to substantiate the therapeutic potential of JRP-SNF102 and its active component, formononetin (FMN), as a functional food that moderates inflammatory responses. The inhibitory effects of JRP-SNF102 or FMN on thymic stromal lymphopoietin (TSLP) levels were evaluated in phorbol 12-myristate 13-acetate (PMA) plus A23187-activated human mast cell line-1 (HMC-1) cells and a mouse model of PMA-induced ear edema. The JRP-SNF102 or FMN inhibited the secretion and mRNA expression of TSLP and vascular endothelial growth factor (VEGF) in the activated HMC-1 cells. The expression levels of murine double minute 2 (MDM2), hypoxia-inducible factor 1α (HIF1α), and NF-κB were also suppressed by JRP-SNF102 or FMN in the activated HMC-1 cells. The JRP-SNF102 or FMN inhibited TSLP and VEGF levels, attenuating redness and ear thickness in mice with acute ear edema; JRP-SNF102 or FMN reduced the expression levels of MDM2, HIF1α, and NF-κB in the ear tissues. These findings suggest the potential for JRP-SNF102 as a functional food in the treatment of inflammatory skin disorders through suppression of TSLP and VEGF.
Collapse
Affiliation(s)
- Na-Ra Han
- College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Hi-Joon Park
- Department of Anatomy & Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Seong-Gyu Ko
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
- Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Phil-Dong Moon
- Center for Converging Humanities, Kyung Hee University, Seoul 02447, Republic of Korea
- Correspondence:
| |
Collapse
|
6
|
Zhang J, Yang X, Chen J, Han J, Chen X, Fan Y, Zheng H. Construction of a diagnostic classifier for cervical intraepithelial neoplasia and cervical cancer based on XGBoost feature selection and random forest model. J Obstet Gynaecol Res 2023; 49:296-303. [PMID: 36220631 DOI: 10.1111/jog.15458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 08/18/2022] [Accepted: 09/23/2022] [Indexed: 01/19/2023]
Abstract
BACKGROUND The pathological phenotype of early-stage cervical cancer (CC) is similar to that of cervical intraepithelial neoplasia (CIN), which provides a challenge for the diagnosis of cervical precancerous lesions. Meanwhile, the existing diagnostic methods have certain subjectivity and limitations, resulting in the possibility of misdiagnosis or missed diagnosis. Hence, some methods are needed to assist diagnosis of CC and CIN. METHODS Based on the data of CIN and CC in gene expression omnibus (GEO) dataset, the eXtreme Gradient Boosting (XGBoost) algorithm was used to screen the feature genes between CIN and CC for constructing the classifier. Incremental feature selection (IFS) curve was also used for screening. The classifier was validated for reliability using principal component analysis (PCA) dimensionality reduction analysis and heat map analysis of gene expression. Then, differentially expressed genes of CIN and CC were intersected with the classifier genes. Genes in the intersection were used as seeds for protein-protein interaction network construction and restart random walk analysis. And the genes with the top 50 affinity coefficients were selected for gene ontology (GO) and kyoto encyclopedia of genes and genome (KEGG) enrichment analyses to observe the biological functions with differences between CIN and CC. RESULTS The peripheral blood genes of CIN and CC were analyzed, and seven genes were screened. Using this gene for classifier construction, IFS curve screening revealed that the three-feature gene classifier constructed according to the random forest model had the best effect. The results of PCA dimensionality reduction analysis and gene expression heat map analysis showed that the three-gene classifier could effectively distinguish CIN from CC. CONCLUSION A three-gene diagnostic classifier can effectively distinguish CIN patients from CC patients and provide a reference for the clinical diagnosis of early CC.
Collapse
Affiliation(s)
- Jing Zhang
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| | - Xiuqing Yang
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| | - Jia Chen
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| | - Jing Han
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| | - Xiaofeng Chen
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| | - Yueping Fan
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| | - Hui Zheng
- Department of Gynaecology and Obstetrics, Jiangsu Xiangshui Hospital of Chinese Medicine, Yancheng, Jiangsu, China
| |
Collapse
|
7
|
Development and Validation of a New Analytical HPLC-PDA Method for Simultaneous Determination of Cucurbitacins B and D from the Roots of Trichosanthes kirilowii. J CHEM-NY 2022. [DOI: 10.1155/2022/2109502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Trichosanthes kirilowii, one of the herbal formulas named SH003, has been used for treatment in traditional medicine. This paper aimed to analyze the marker compounds from the roots of T. kirilowii and evaluate a validation method for cucurbitacins B and D using high-performance liquid chromatography-photodiode array detector (HPLC-PDA). Two marker compounds were identified as cucurbitacin B (1) and cucurbitacin D (2) from the roots of T. kirilowii by spectroscopic analyses. Cucurbitacins B and D peaks were well separated and were detected at 15.4 min and 12.4 min, respectively, by a UV detector at 230 nm with the linearity (R2 > 0.999) range between 5 and 250 μg/mL, limit of detections (LODs) were 1.87 μg/mL and 1.30 μg/mL, respectively, while limit of quantifications (LOQs) were 5.66 μg/mL and 3.93 μg/mL, respectively. The established method offered good precision with overall intra- and inter-day variations of 0.34–1.26 and 0.26–1.35%, respectively, for % relative standard deviation (RSD, acceptance limit %RSD <3%). The cucurbitacins B and D recoveries ranged from 99.2 to 101.7% and 98.6 to 102.0%, respectively. These results suggest that cucurbitacins B and D could be a valuable candidate for marker compounds of the extract from T. kirilowii, and the proposed method was shown applicability for quality control of SH003.
Collapse
|
8
|
Han NR, Kim KC, Kim JS, Ko SG, Park HJ, Moon PD. The immune-enhancing effects of a mixture of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) or its active constituent nodakenin. JOURNAL OF ETHNOPHARMACOLOGY 2022; 285:114893. [PMID: 34875347 DOI: 10.1016/j.jep.2021.114893] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 11/16/2021] [Accepted: 12/01/2021] [Indexed: 06/13/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE A mixture (SH003) of Astragalus membranaceus (Fisch.) Bunge, Angelica gigas Nakai, and Trichosanthes Kirilowii (Maxim.) has beneficial effects against several carcinomas. There have been few reports on an immune-enhancing activity of SH003 and its active constituent nodakenin. AIM OF THE STUDY This study aimed at identifying the immune-enhancing effect of SH003 and nodakenin. MATERIALS AND METHODS The immune-enhancing effect was evaluated using RAW264.7 macrophages, mouse primary splenocytes, and a cyclophosphamide (CP)-induced immunosuppression murine model. RESULTS The results show that SH003 or nodakenin stimulated the production levels of granulocyte colony-stimulating factor, IL-12, IL-2, IL-6, TNF-α, and nitric oxide (NO) and the expression levels of iNOS in RAW264.7 macrophages. SH003 or nodakenin also enhanced NF-κB p65 activation in RAW264.7 macrophages. SH003 or nodakenin stimulated the production levels of IFN-γ, IL-12, IL-2, TNF-α, and NO and the expression levels of iNOS in splenocytes. SH003 or nodakenin increased the splenic lymphocyte proliferation and splenic NK cell activity. In addition, SH003 or nodakenin increased the levels of IFN-γ, IL-12, IL-2, IL-6, and TNF-α in the serum and spleen of CP-treated mice, alleviating CP-induced immunosuppression. CONCLUSION Taken together, the results of this study show that SH003 improved immunosuppression through the activation of macrophages, splenocytes, and NK cells. These findings suggest that SH003 could be applied as a potential immunostimulatory agent for a variety of diseases caused or exacerbated by immunodeficiency.
Collapse
Affiliation(s)
- Na-Ra Han
- College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea; Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
| | - Kyeoung-Cheol Kim
- Majors in Plant Resource and Environment, College of Agriculture & Life Sciences, SARI, Jeju National University, Jeju, 63243, Republic of Korea.
| | - Ju-Sung Kim
- Majors in Plant Resource and Environment, College of Agriculture & Life Sciences, SARI, Jeju National University, Jeju, 63243, Republic of Korea.
| | - Seong-Gyu Ko
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea; Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
| | - Hi-Joon Park
- Department of Anatomy & Information Sciences, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
| | - Phil-Dong Moon
- Center for Converging Humanities, Kyung Hee University, Seoul, 02447, Republic of Korea.
| |
Collapse
|
9
|
State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent. Cancers (Basel) 2022; 14:cancers14041089. [PMID: 35205836 PMCID: PMC8870567 DOI: 10.3390/cancers14041089] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 02/17/2022] [Accepted: 02/18/2022] [Indexed: 12/04/2022] Open
Abstract
Cancer ranks as the first leading cause of death globally. Despite the various types of cancer treatments, negative aspects of the treatments, such as side effects and drug resistance, have been a continuous dilemma for patients. Thus, natural compounds and herbal medicines have earned profound interest as chemopreventive agents for reducing burden for patients. SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, showed the potential to act as an anticancer agent in previous research studies. A narrative review was conducted to present the significant highlights of the total 15 SH003 studies from the past nine years. SH003 has shown positive results in both in vivo and vitro studies against various types of cancer cells; furthermore, the first clinical trial was performed to identify the maximum tolerated dose among solid cancer patients. So far, the potential of SH003 as a chemotherapeutic agent has been well-documented in research studies; continuous work on SH003's efficacy and safety is required to facilitate better cancer patient care but is part of the knowledge needed to understand whether SH003 has the potential to become a pharmaceutical.
Collapse
|
10
|
Sheik A, Kim K, Varaprasad GL, Lee H, Kim S, Kim E, Shin JY, Oh SY, Huh YS. The anti-cancerous activity of adaptogenic herb Astragalus membranaceus. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2021; 91:153698. [PMID: 34479785 DOI: 10.1016/j.phymed.2021.153698] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 07/21/2021] [Accepted: 07/31/2021] [Indexed: 05/28/2023]
Abstract
BACKGROUND Cancer is the most dreadful disease increasing rapidly causing an economic burden globally. A standardized chemotherapy regimen planned with curative intent weakens the immune system and damages healthy cells making the patient prone to infections and severe side effects with pain and fatigue. PURPOSE Astragalus membranaceus (AM) has a long history of use in the treatment of severe adverse diseases. For thousands of years, it has been used in mixed herbal decoctions for the treatment of cancer. Due to growing interest in this plant root for its application to treat various types of cancers and tumors, has attracted researcher's interest. METHOD The literature search was done from core collections of electronic databases such as Web of Science, Google Scholar, PubMed and Science Direct using keywords given below and terms like pharmacological and phytochemical details of this plant. OUTCOME Astragalus membranaceus has demonstrated the ability to modulate the immune system during drug therapy making the patient physically fit and prolonged life. It has become a buzzword of herbalists as it is one of the best of seven important adaptogenic herbs with a protective effect against chronic stress and cancer. It demonstrated significant amelioration of the perilous toxic effects induced by concurrently administered chemo onco-drugs. CONCLUSION The natural phytoconstituents of this plant formononetin, astragalus polysaccharide, and astragalosides which show high potential anti-cancerous activity are studied and discussed in detail. One of them are used in clinical trials to overcome cancer related fatigue. Overall, this review aims to provide an insight into Astragalus membranaceus status in cancer therapy.
Collapse
Affiliation(s)
- Aliya Sheik
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
| | - Kwanwoo Kim
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
| | - Ganji Lakshmi Varaprasad
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
| | - Hoomin Lee
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
| | - Suheon Kim
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
| | - Eunsu Kim
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea
| | - Jin-Yong Shin
- Chungcheong Division Reliability Center, Korea Confomity Laboratories, Yuseong-gu, Daejeon, 34027, Republic of Korea
| | - Seo Yeong Oh
- Research Group of Consumer Safety, Korea Food Research Institute, 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun, Jeollabuk-do 55365, Korea.
| | - Yun Suk Huh
- NanoBio High-Tech Materials Research Center, Department of Biological Engineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea.
| |
Collapse
|
11
|
Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer. Int J Mol Sci 2021; 22:ijms22168405. [PMID: 34445110 PMCID: PMC8395077 DOI: 10.3390/ijms22168405] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 08/01/2021] [Accepted: 08/02/2021] [Indexed: 12/26/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) is overexpressed in lung cancer patients. Despite treatment with various EGFR tyrosine kinase inhibitors, recurrence and metastasis of lung cancer are inevitable. Docetaxel (DTX) is an effective conventional drug that is used to treat various cancers. Several researchers have studied the use of traditional herbal medicine in combination with docetaxel, to improve lung cancer treatment. SH003, a novel herbal mixture, exerts anticancer effects in different cancer cell types. Here, we aimed to investigate the apoptotic and anticancer effects of SH003 in combination with DTX, in human non-small-cell lung cancer (NSCLC). SH003, with DTX, induced apoptotic cell death, with increased expression of cleaved caspases and cleaved poly (ADP-ribose) polymerase in NSCLC cells. Moreover, SH003 and DTX induced the apoptosis of H460 cells via the suppression of the EGFR and signal transducer and activator of transcription 3 (STAT3) signaling pathways. In H460 tumor xenograft models, the administration of SH003 or docetaxel alone diminished tumor growth, and their combination effectively killed cancer cells, with increased expression of apoptotic markers and decreased expression of p-EGFR and p-STAT3. Collectively, the combination of SH003 and DTX may be a novel anticancer strategy to overcome the challenges that are associated with conventional lung cancer therapy.
Collapse
|
12
|
Shen L, Gwak SR, Cui ZY, Joo JC, Park SJ. Astragalus-Containing Chinese Herbal Medicine Combined With Chemotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 2021; 12:587021. [PMID: 34393766 PMCID: PMC8361476 DOI: 10.3389/fphar.2021.587021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 06/30/2021] [Indexed: 01/04/2023] Open
Abstract
Background: Cervical cancer is the fourth most common malignant tumor among women worldwide. This study aimed to evaluate the efficacy of Astragalus-containing Chinese herbal medicine (CHM) combined with chemotherapy (CT) for the treatment of cervical cancer. Methods: Ten electronic databases including PubMed, Cochrane Library, Embase, Korean databases, and Chinese medical databases, were systematically searched up to July 2020. All randomized controlled trials using Astragalus-containing CHM combined with CT to treat cervical cancer were included. Results: A total of 19 trials were included in the analysis. Compared with the control group, the Astragalus-containing CHM combined with CT group showed a significantly increased tumor response (complete and partial response (CR and PR)) (risk ratio [RR] = 1.25, 95% confidence interval [CI]: 1.17–1.33, p < 0.00001) and Karnofsky performance score (KPS) (standardized mean difference [SMD] = 1.81, 95% CI: 1.46–2.17, p < 0.00001). This group also displayed remarkably reduced CT toxicity. Conclusion: Our study suggests that Astragalus-containing CHM might be a potential option for cervical cancer to enhance the curative efficacy and reduce CT toxicity.
Collapse
Affiliation(s)
- Lei Shen
- Aerospace Center Hospital, Beijing, China
| | - Si Ra Gwak
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan, South Korea
| | - Zhen Yang Cui
- Rehabilitation Medicine College, Weifang Medical University, Weifang, China
| | - Jong Cheon Joo
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan, South Korea
| | - Soo Jung Park
- Department of Sasang Constitutional Medicine, College of Korean Medicine, Woosuk University, Jeonju, South Korea
| |
Collapse
|
13
|
Elucidation of rutin's role in inducing caspase-dependent apoptosis via HPV-E6 and E7 down-regulation in cervical cancer HeLa cells. Biosci Rep 2021; 41:228976. [PMID: 34109976 PMCID: PMC8220446 DOI: 10.1042/bsr20210670] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Revised: 05/06/2021] [Accepted: 05/17/2021] [Indexed: 02/06/2023] Open
Abstract
Over the recent few years rutin has gained wider attention in exhibiting inhibitory potential against several oncotargets for inducing apoptotic and antiproliferative activity in several human cancer cells. Several deregulated signaling pathways are implicated in cancer pathogenesis. Therefore we have inclined our research towards exploring the anticancerous efficacy of a very potent phytocompound for modulating the incontinent expression of these two crucial E6 and E7 oncogenes. Further, inhibitory efficacy of rutin against human papillomavirus (HPV)-E6 and E7 oncoproteins in cervical cancer has not been elucidated yet. This research addresses the growth inhibitory efficacy of rutin against E6 and E7 oncoproteins in HeLa cells, which is known to inactivate several tumor suppressor proteins such as p53 and pRB. Rutin treatment exhibited reduced cell viability with increased cell accumulation in G0/G1 phase of cell cycle in HeLa cell lines. Additionally, rutin treatment has also led to down-regulation of E6 and E7 expression associated with an increased expression of p53 and pRB levels. This has further resulted in enhanced Bax expression and decreased Bcl-2 expression releasing cytochrome c into cytosol followed by caspase cascade activation with cleavage of caspase-3, caspase-8 and caspase-9. Further, in silico studies have also supported our in vitro findings by exhibiting significant binding energy against selected target oncoproteins. Therefore, our research findings might recommend rutin as one of the potent drug candidate in cervical cancer management via targeting two crucial oncoproteins associated with viral progression.
Collapse
|
14
|
Cheon C, Ko SG. A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer. Integr Cancer Ther 2021; 19:1534735420911442. [PMID: 32186413 PMCID: PMC7081467 DOI: 10.1177/1534735420911442] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background: Cancer is a major health problem worldwide and the
leading cause of death in many countries. Preclinical studies have shown the
therapeutic anticancer effects of SH003, a novel herbal medicine containing
Astragalus membranaceus, Angelica gigas, and
Trichosanthes kirilowii. The present study investigated the
maximum tolerated dose of SH003 in patients with solid cancers.
Methods: This open-label, dose-escalation trial used the
traditional 3 + 3 dose-escalation design. Patients with solid cancers were
recruited and administered 1 to 4 tablets of SH003 thrice daily for 3 weeks
according to the dose level. Adverse events were evaluated according to the
Common Terminology Criteria for Adverse Events (CTCAE). Dose-limiting toxicities
(DLTs) were defined as Grade 3 or higher adverse events based on CTCAE. The
maximum tolerated dose was defined as the highest dose at which no more than 1
of 6 patients experienced DLT. Results: The present study enrolled
11 patients. A total of 31 adverse events occurred. According to the CTCAE, all
the observed adverse events were grade 2 or less and no adverse events of grade
3 or more corresponding to DLT occurred. Conclusion: The study
results indicated that the maximum tolerated dose of SH003 was 4800 mg/day. A
Phase 2 study is required to determine the efficacy of SH003 in patients with
cancer at a dose of 4800 mg/day or less.
Collapse
Affiliation(s)
- Chunhoo Cheon
- Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
| | - Seong-Gyu Ko
- Department of Korean Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
| |
Collapse
|
15
|
Therapeutic Potential of Natural Products in Treatment of Cervical Cancer: A Review. Nutrients 2021; 13:nu13010154. [PMID: 33466408 PMCID: PMC7824868 DOI: 10.3390/nu13010154] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 01/03/2021] [Accepted: 01/03/2021] [Indexed: 12/24/2022] Open
Abstract
Cervical cancer is the fourth most common cancer among women worldwide. Though several natural products have been reported regarding their efficacies against cervical cancer, there has been no review article that categorized them according to their anti-cancer mechanisms. In this study, anti-cancerous natural products against cervical cancer were collected using Pubmed (including Medline) and google scholar, published within three years. Their mechanisms were categorized as induction of apoptosis, inhibition of angiogenesis, inhibition of metastasis, reduction of resistance, and regulation of miRNAs. A total of 64 natural products suppressed cervical cancer. Among them, Penicillium sclerotiorum extracts from Cassia fistula L., ethanol extracts from Bauhinia variegate candida, thymoquinone obtained from Nigella sativa, lipid-soluble extracts of Pinellia pedatisecta Schott., and 1'S-1'-acetoxychavicol extracted from Alpinia conchigera have been shown to have multi-effects against cervical cancer. In conclusion, natural products could be attractive candidates for novel anti-cancer drugs.
Collapse
|
16
|
Cheon C, Ko SG. Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol. Medicine (Baltimore) 2020; 99:e22228. [PMID: 32957363 PMCID: PMC7505292 DOI: 10.1097/md.0000000000022228] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
INTRODUCTION Cancer is the second leading cause of death, and the burden of cancer continues to grow globally. Research on the efficacy of combined administration of herbal medicine and anticancer drugs is also increasing. SH003 is a new herbal medicine composed of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii. SH003 alone up to 4800 mg daily was found to be safe. Preclinical studies have shown SH003 to have a synergistic effect with coadministration of anticancer drugs. This study aimed to determine the maximum tolerated dose of SH003 combined with docetaxel in patients with lung or breast cancer. METHODS This is an open-label, dose-escalation study to evaluate the safety of SH003 combined with docetaxel. Patients with lung or breast cancer will be recruited. The participants will be divided into 3 groups based on SH003 daily dose (2400, 3600, and 4800 mg); the medication will be taken orally for 21 days. The traditional 3 + 3 design will be adopted for the dose escalation. Dose-limiting toxicities are defined as grade 3 or 4 adverse events according to the Common Terminology Criteria for Adverse Events. The highest dose at which no more than 1 of the 6 patients experience dose-limiting toxicity will be determined as the maximum tolerated dose of SH003 combined with docetaxel. DISCUSSION This study investigates the safety of SH003 when combined with docetaxel. The results of this study will provide a safe dose range for conducting therapeutic exploratory trials. TRIAL REGISTRATIONS ClinicalTrials.gov NCT04360317.
Collapse
|
17
|
Wang F, Song X, Ma S, Liu C, Sun X, Wang X, Liu Z, Liang D, Yu Z. The treatment role of Cyperus rotundus L. to triple-negative breast cancer cells. Biosci Rep 2019; 39:BSR20190502. [PMID: 31123166 PMCID: PMC6554218 DOI: 10.1042/bsr20190502] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 04/23/2019] [Accepted: 05/20/2019] [Indexed: 12/31/2022] Open
Abstract
Cyperus rotundus L. is widely used in Traditional Chinese Medicine and studies have reported its anticancer effect, but its chemical composition and therapy mechanism remains unknown. This research aims to analyze the chemical components of the ethanol extract of Cyperus rotundus L. (EECR), detect its treatment effects on human Triple-negative breast cancer (TNBC) cells, and elucidate possible therapy mechanisms. The chemical components of EECR were detected by the Waters UPLC combined with Bruker Q-TOF mass spectrometer (UPLC-Q-TOF-MS). The phytochemical compounds were identified by comparing the mass fragmentations of each metabolite with databases such as METLIN, HMDB, and NCBI. A total of 21 compounds were identified in EECR. MDA-MB-231 and MDA-MB-468 cells were treated with various concentrations of EECR. Cell proliferation was examined using Cell Counting Kit-8 (CCK-8) and colony formation assays. Cell apoptosis and cell cycle were detected by flow cytometry. Apoptosis- and autophagy-related protein expression was detected by Western blot. EECR inhibits the proliferation of TNBC cells (MDA-MB-231 and MDA-MB-468) in a dose-dependent manner, which may be related to the arrest of cell cycle in G0/G1 phase. It induces apoptosis by promoting the expression of BAX and inhibiting the expression of BCL-2. In addition, autophagy inhibitor 3-Methyladenine (3-MA) inhibited TNBC cells pro-survival autophagy and increased the sensitivity of EECR. The present results demonstrated that EECR has potential effects on inhibits the proliferation and induction apoptosis in TNBC.
Collapse
Affiliation(s)
- Fukai Wang
- Department of Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250017, China
- Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Xiang Song
- Department of Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250017, China
- School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong 250017, China
| | - Shuangshuang Ma
- Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong 250014, China
| | - Chenyu Liu
- Department of Physiology, Georgetown University School of Medicine, Washington, DC 20057, U.S.A
| | - Xiaohui Sun
- Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
- Department of Breast Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Xinzhao Wang
- Department of Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250017, China
| | - Zhaoyun Liu
- Department of Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250017, China
| | - Dong Liang
- Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
- Department of Breast Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China
| | - Zhiyong Yu
- Department of Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250017, China
| |
Collapse
|
18
|
Zhu Y, Mi Y, Wang Z, Jia X, Jin Z. Norcantharidin inhibits viability and induces cell cycle arrest and apoptosis in osteosarcoma. Oncol Lett 2018; 17:456-461. [PMID: 30655787 DOI: 10.3892/ol.2018.9615] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Accepted: 08/22/2018] [Indexed: 12/28/2022] Open
Abstract
Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be elucidated. In the current study, it was first demonstrated that NCTD inhibited proliferation and induced G2/M-phase arrest and cell apoptosis in human osteosarcoma cells. Furthermore, NCTD significantly decreased the phosphorylation of Akt and the mammalian target of rapamycin in human osteosarcoma cells. These results suggest that NCTD is a promising candidate for the treatment of osteosarcoma patients in the future.
Collapse
Affiliation(s)
- Yingchun Zhu
- Department of Orthopedics, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China
| | - Yunfeng Mi
- Department of Orthopedics, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China
| | - Zheyang Wang
- Department of Orthopedics, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China
| | - Xuewen Jia
- Department of Orthopedics, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China
| | - Zhanping Jin
- Department of Orthopedics, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China
| |
Collapse
|